ISOPP 2022 Virtual Symposium BD Session: Introducing a novel CSTD to protect healthcare workers and reduce contamination across preparation and administration areas in a multisite health system

Video

Date posted:
March 2022
Date resource created:
March 21, 2022
Subject:
Symposium: Plenary
Content Type:
Symposium (International)
File type:
Video (Presentation)
Presenter(s):
Erich Brechtelsbauer, Assistant Director of Pharmacy, Emory Healthcare & Winship Cancer Institute, Atlanta, Georgia, United States

Education Need

The use of closed system drug transfer devices (CSTDs) for the preparation of hazardous drugs (HDs) is recommended by several international organizations including the International Society of Oncology Pharmacy Practitioners (ISOPP), the United States Pharmacopeia (USP) Chapter <800>, the American Society of Health System Pharmacists (ASHP), and the US National Institute for Occupational Safety and Health (NIOSH).  However, there is no current performance standard for devices marketed as CSTDs, so clinical evidence is important when selecting a CSTD for use.  The BD PhaSeal™ Optima System CSTD received clearance by the FDA under the ONB code in 2018 and was deemed substantially equivalent to the BD PhaSeal™ System CSTD.   Despite manufacturer evidence of performance for vapor containment, leakage, and prevention of microbial ingress, there is a paucity of third-party evidence validating its performance in practice. 

Learning Objectives

  1. Understand international guidelines and standards related to the use of closed system drug transfer devices (CSTDs) for preparation and administration of hazardous drugs (HDs)
  2. Describe the approach to selecting and implementing a CSTD in multisite health system
  3. Identify locations and technology to detect HD contamination
  4. Explain the impact of using the BD PhaSeal™ Optima system on HD surface contamination levels in both pharmacy and patient care areas

Agenda

  1. Introduction (5 minutes) by Ryan Forrey
  2. Use of a novel CSTD to reduce contamination in an oncology pharmacy and infusion center (45 minutes) by Erich Brechtelsbauer
  3. Questions, Answers, and Discussion (10 minutes)